3BNC117 - A Novel Broad-spectrum HIV Neutralizing Antibody

Product description

3BNC117 is one of the most effective broad-spectrum HIV neutralizing antibodies. Several phase 1 and phase 2 clinical trials have been conducted in the US, showing 3BNC117 not only blocks viral replication like other AIDS drugs, but also induces immune response to HIV and HIV-infected cells. Combining 3BNC117 with ALBUVIRTIDE, we will form an all-injectable, long-acting, two-drug regimen that has novel mechanism of action. We plan to initiate clinical trials in 2018 to test its safety, effectiveness, and potential in eliciting immune response to HIV infection.

Read more


Categories APIsAntibodies; BiopharmaceuticalsImmunology; Finished Dosage FormsInjectables
Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Supplied from China
Measured In g; mg
Selling Points Immune Health; Product Features; Quality Service
Show more specifications

Products from other suppliers

3BNC117 - A Novel Broad-spectrum HIV Neutralizing Antibody

Contact information




View all contact information